Your browser is no longer supported. Please, upgrade your browser.
Settings
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own2.70% Shs Outstand59.22M Perf Week7.17%
Market Cap354.14M Forward P/E- EPS next Y-1.37 Insider Trans0.00% Shs Float55.97M Perf Month12.62%
Income-80.80M PEG- EPS next Q-0.37 Inst Own35.00% Short Float17.85% Perf Quarter1.01%
Sales0.30M P/S1180.45 EPS this Y-28.30% Inst Trans-0.57% Short Ratio22.69 Perf Half Y71.84%
Book/sh1.25 P/B4.78 EPS next Y2.10% ROA-66.80% Target Price9.56 Perf Year-3.31%
Cash/sh1.04 P/C5.76 EPS next 5Y7.33% ROE-79.00% 52W Range3.07 - 9.36 Perf YTD-2.76%
Dividend- P/FCF- EPS past 5Y-26.90% ROI-86.50% 52W High-36.32% Beta2.37
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin- 52W Low94.14% ATR0.26
Employees104 Current Ratio4.70 Sales Q/Q0.00% Oper. Margin- RSI (14)56.38 Volatility4.25% 4.37%
OptionableYes Debt/Eq0.01 EPS Q/Q60.60% Profit Margin- Rel Volume0.56 Prev Close5.98
ShortableYes LT Debt/Eq0.01 EarningsAug 04 AMC Payout- Avg Volume440.46K Price5.96
Recom2.40 SMA205.14% SMA504.18% SMA20013.88% Volume82,528 Change-0.33%
May-19-16Initiated Chardan Capital Markets Buy $12
Sep-25-15Reiterated Piper Jaffray Overweight $12 → $20
Oct-09-14Downgrade RBC Capital Mkts Outperform → Sector Perform $35 → $9
Mar-05-14Initiated RBC Capital Mkts Outperform $35
Mar-05-14Initiated Deutsche Bank Buy $45
Feb-26-13Initiated Dawson James Buy $4
Jul-22-16 08:20AM  Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US : July 22, 2016
Jul-11-16 08:40AM  Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARWR-US : July 11, 2016
Jul-06-16 07:30AM  Arrowhead Pharmaceuticals to Present at Cantor Fitzgeralds 2nd Annual Healthcare Conference Business Wire
Jul-01-16 05:54PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : July 1, 2016
Jun-27-16 09:05AM  Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US : June 27, 2016 -6.03%
Jun-17-16 11:53AM  Arrowhead Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARWR) : June 17, 2016
Jun-15-16 08:10AM  Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US : June 15, 2016
Jun-09-16 07:30AM  Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521 Business Wire
Jun-03-16 07:30AM  Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference Business Wire
May-23-16 08:05AM  10 Speculative Biotech and Biohealth Stocks With Massive Analyst Upside Calls at 24/7 Wall St.
May-20-16 01:00PM  ARWR: Update on Financials for Fiscal Second Quarter Ended March 31, 2016 +8.18%
May-19-16 01:04PM  ARROWHEAD PHARMACEUTICALS, INC. Financials
06:09AM  Coverage initiated on Arrowhead by Chardan Capital Markets
May-17-16 08:05PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 18, 2016
12:15PM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q2, 2016 By the Numbers
May-16-16 08:31AM  Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US : May 16, 2016
May-11-16 01:31AM  Edited Transcript of ARWR earnings conference call or presentation 10-May-16 8:30pm GMT
May-10-16 04:11PM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
04:09PM  Arrowhead Research reports 2Q loss
04:01PM  Arrowhead Reports Fiscal 2016 Second Quarter Results Business Wire
07:07AM  Q2 2016 Arrowhead Pharmaceuticals Inc Earnings Release - After Market Close
May-06-16 12:00PM  Arrowhead Pharmaceuticals Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration Business Wire
May-03-16 04:01PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results Business Wire
Apr-29-16 07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming May Conferences Business Wire
Apr-28-16 07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 Business Wire
Apr-25-16 06:01PM  Can Arrowhead Do For Hep B What Gilead Sciences Did For Hep C? at Motley Fool
Apr-18-16 02:00PM  Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016 Business Wire
09:05AM  Time For Another Biotech Rally Accesswire
Apr-14-16 04:56PM  Here's Why Arrowhead Pharma (ARWR) Stock Closed Up Today at TheStreet
09:57AM  4 Hot Trending Small Cap Stocks That You Haven't Heard About Accesswire
09:21AM  Better Buy: Inovio Pharmaceuticals or Arrowhead Research Corp.? at Motley Fool
Apr-13-16 04:57PM  What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today at Motley Fool +12.93%
03:36PM  Arrowhead Pharma (ARWR) Stock Spikes on Promising Hepatitis B Data at TheStreet
02:42PM  Why JPMorgan (JPM), Facebook (FB), and Fitbit (FIT) Are Among Todays Trending Stocks at Insider Monkey
07:30AM  Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress 2016 Business Wire
Apr-06-16 05:19PM  ARROWHEAD RESEARCH CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia
04:01PM  Arrowhead Research Changes Name to Arrowhead Pharmaceuticals Business Wire
Mar-30-16 07:40AM  Arrowhead to Present at Upcoming April Conferences at noodls
07:30AM  Arrowhead to Present at Upcoming April Conferences Business Wire
Mar-10-16 04:10PM  ARROWHEAD RESEARCH CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Mar-07-16 12:45PM  Arrowhead Presents Promising New Preclinical Data on ARC-F12 at AAAAI 2016 Business Wire +9.93%
Mar-01-16 07:30AM  Arrowhead to Present at Upcoming March Conferences Business Wire +6.15%
Feb-16-16 04:33PM  Arrowhead to Present at Upcoming February Conferences Business Wire +5.95%
01:57PM  Arrowhead Research Corp. Earnings Analysis: Q1, 2016 By the Numbers
Feb-09-16 04:45PM  Arrowhead Research reports 1Q loss
04:12PM  ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
04:01PM  Arrowhead Reports Fiscal 2016 First Quarter Results Business Wire
07:07AM  Q1 2016 Arrowhead Research Corp Earnings Release - After Market Close
Feb-02-16 04:01PM  Arrowhead to Webcast Fiscal 2016 First Quarter Results Business Wire -5.80%
Jan-19-16 04:20PM  Why Shares in Arrowhead Research Dropped Over 15% Today at Motley Fool -16.16%
07:30AM  Arrowheads ARC-AAT Granted EMA Orphan Drug Designation Business Wire
Jan-14-16 04:11PM  ARROWHEAD RESEARCH CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia
Jan-13-16 08:00AM  Healthcare Sector Equities under Review -- Amarin, Arrowhead Research, Zogenix, and PetMed Express Accesswire -6.63%
Jan-07-16 08:06AM  Arrowhead Research Corp. breached its 50 day moving average in a Bearish Manner : January 7, 2016
07:30AM  Arrowhead Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic Hepatitis B Infection Business Wire
Dec-28-15 08:00AM  Technical Coverage on Biotechnology Stocks - Agenus, Progenics Pharma, Arrowhead Research, and Infinity Pharma Accesswire
Dec-18-15 09:48AM  5 Stocks Ready for Breakouts at TheStreet
08:00AM  Pre-market Equity Watch on Biotechnology -- Agenus, Arrowhead Research, Spectrum Pharma, and Infinity Pharma Accesswire
Dec-15-15 01:27AM  Edited Transcript of ARWR earnings conference call or presentation 14-Dec-15 9:30pm GMT
Dec-14-15 04:37PM  Arrowhead Research reports 4Q loss
04:30PM  Arrowhead Research Corp Earnings Call scheduled for 4:30 pm ET today
04:01PM  Arrowhead Reports Fiscal 2015 Year End Results Business Wire
03:52PM  ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
03:49PM  ARROWHEAD RESEARCH CORP Files SEC form 10-K, Annual Report
01:16PM  Arrowhead Added to NASDAQ Biotechnology Index® Business Wire
11:42AM  5 Stocks Set to Soar on Bullish Earnings at TheStreet
07:07AM  Q4 2015 Arrowhead Research Corp Earnings Release - After Market Close
Dec-11-15 07:30AM  Today's Market Driven by Key Factors - Analyst Notes on Arrowhead Research, Omeros Corp, TriMas and Applied Micro Circuits Accesswire
Dec-08-15 01:30PM  ARWR: Update on ARC-520 Chimpanzee Data
08:44AM  Arrowhead Research Due Diligence Report: Tailwinds Ahead for this Researcher Accesswire
12:01AM  Why Keurig Green Mountain, Arrowhead Research, and Smith & Wesson Jumped on Monday at Motley Fool
Dec-07-15 04:01PM  Arrowhead to Webcast Fiscal 2015 Year End Results Business Wire +12.64%
07:30AM  Arrowheads ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection Business Wire
Nov-27-15 10:06AM  Do Hedge Funds Love Navidea Biopharmaceuticals Inc (NAVB)? at Insider Monkey
Nov-25-15 11:50AM  Arrowhead Research Corp. Value Analysis (NASDAQ:ARWR) : November 25, 2015 +5.01%
08:29AM  Arrowhead Research Corp. breached its 50 day moving average in a Bullish Manner : November 25, 2015
Nov-19-15 09:42AM  Actinium: An Interesting Stock In The Small Cap Biotech Space
Nov-16-15 12:06PM  Arrowhead Research (ARWR) Stock Rises on Clinical Trial Results at TheStreet
11:00AM  Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA Business Wire
Nov-15-15 06:15PM  Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees Business Wire
Nov-11-15 07:30AM  Arrowhead to Present at Upcoming Conferences Business Wire +5.50%
Oct-20-15 10:00AM  Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015 Business Wire
Oct-14-15 09:30AM  Arrowhead Presents Overview of Its Broad RNAi Delivery Platform and Introduces New Subcutaneously Administered Format Business Wire
Oct-05-15 07:30AM  Arrowhead to Present at Upcoming Conferences Business Wire +6.90%
Oct-01-15 11:02AM  Arrowhead Research Corp. Earnings Q3, 2015
Sep-30-15 12:18PM  Arrowheads HBV Trial Success Could Attract Buyers; Are Gilead Or Bristol-Myers Paying Attention?
11:21AM  ETFs with exposure to Arrowhead Research Corp. : September 30, 2015
09:46AM  Arrowhead Research Corp. breached its 50 day moving average in a Bearish Manner : September 30, 2015
Sep-29-15 09:50AM  ARWR: Update on Arrowheads ARC-520 Phase IIa HBV Program -8.73%
Sep-28-15 04:47PM  10 Stocks Moving In Monday's After-Hours Session -13.22%
Sep-25-15 12:04PM  'We're Confident Arrowhead's ARC-520 Is Active Drug For HBV,' Piper Jaffray Says
08:01AM  Trending Now: ARWR
Sep-24-15 01:59PM  See Which of These Two Surging Biotech Stocks Hedge Funds Approve On at Insider Monkey +6.68%
01:36PM  Arrowhead's hep B data shows promise, shares jump
12:03PM  Here's Why Arrowhead Research Corp.'s Stock Bolted Higher Today at Motley Fool
11:38AM  Arrowhead Research (ARWR) Stock Spikes on Positive Test Results at TheStreet
10:51AM  Arrowhead Hits Target In Hepatitis B Drug Trial at Investor's Business Daily
10:33AM  Mid-Morning Market Update: Markets Tumble; Accenture Tops Q4 Estimates
09:30AM  Stocks to Watch: Caterpillar, GE, Accenture, KB Home at The Wall Street Journal
09:30AM  Arrowhead Research Shares Soar on Hepatitis B Study Results at The Wall Street Journal
Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company, develops novel drugs to treat intractable diseases in the United States. The company utilizes its proprietary Dynamic Polyconjugate platform to develop targeted drugs based on the RNA interference mechanism that silences disease-causing genes. Its ARC-520, an RNAi-based therapeutic that is in Phase IIb clinical efficacy studies to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic, which is in Phase Ib clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. The company's pre-clinical stage drug candidates include ARC-521, an RNAi-based therapeutic for the treatment of chronic hepatitis B virus; ARC-F12, an RNAi-based therapeutic to treat hereditary angioedema and thromboembolic diseases; ARC-HIF2, an RNAi-based therapeutic to treat renal cell carcinoma; and ARC-LPA, an RNAi-based therapeutic for the treatment of cardiovascular diseases. It also holds patents related to Adipotide for the treatment of obesity and related metabolic disorders. The company has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anzalone Christopher RichardChief Executive OfficerJun 30Option Exercise5.0915,77280,2791,117,233Jul 05 06:11 PM
Myszkowski Kenneth AllenChief Financial OfficerDec 30Sale6.1323,347143,11785,000Jan 04 07:19 PM